BioSpace News Archive

Redwood Pharma AB (publ) announces positive results from the company’s clinical study with RP501, a medical technology self-care product being developed for the treatment of dry eye.

Brii Biosciences Limited (“Brii Bio” or the “Company”, stock code: 2137.HK) today announced the first subject has been dosed in a Phase 1 clinical trial evaluating BRII-297, a first-of-its-kind long-acting injectable (LAI), in development for the treatment of various anxiety and depressive disorders.

Antengene Corporation Limited announced that XPOVIO® in combination with bortezomib and dexamethasone is now listed on the PBS for the treatment of adult patients with R/R MM who have received at least one prior therapy.

Abcuro, Inc. today announced completion of enrollment of the sentinel cohort of a Phase 2/3 study of ABC008 for the treatment of inclusion body myositis (IBM).

AI Proteins, Inc., a growing biotechnology company that utilizes computational de novo protein design to create novel therapeutic miniproteins, today announced the formation of a Scientific Advisory Board.

New data, being presented in a late-breaking session at the 2023 Consortium of Multiple Sclerosis Centers annual meeting, demonstrate that frexalimab, Sanofi’s novel second-generation investigational anti-CD40L antibody, with a unique mechanism of action, significantly reduced disease activity in a Phase 2 trial of patients with relapsing multiple sclerosis.